May 2013  << Back  

An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics

Brenda Vincenzi, MD

Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA

Christina P. C. Borba, PhD, MPH

Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Deborah A. Gray, MBA, MS

Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA

Paul M. Copeland, MD

Harvard Medical School, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

Xingyue Wang, ScB

Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA

Xiaoduo Fan, MD

Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Gowri G. Aragam, AB

Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA

David C. Henderson, MD

Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

BACKGROUND: We present a retrospective study examining response to treatment with fibrates or statins in schizophrenia patients.

METHODS: We identified the patient population using the Research Patient Data Registry. Demographic data, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and non-HDL cholesterol (non–HDL-C) levels were obtained before initiation of treatment with lipid-lowering medication (LLM) and after LLM treatment was initiated (N = 183).

RESULTS: Treatment with LLMs resulted in a statistically significant decrease in total cholesterol, triglycerides, LDL-C, and non–HDL-C. An independent-samples t test comparing the statin treatment–alone group with the fibrate treatment–alone group showed a significant reduction in triglyceride levels from baseline to 1-year follow-up in the fibrate treatment–alone group.

CONCLUSIONS: The results of this study indicate that schizophrenia patients respond to LLMs in a manner consistent with the general population. Future studies would benefit from a larger sample, as well as comparisons between more specific treatment groups, such as those defined by type of statin or fibrate, to observe differential effects on specific markers of dyslipidemia in this population.

KEYWORDS: schizophrenia, fibrate treatment, statin treatment, metabolic disorders, atypical antipsychotics

ANNALS OF CLINICAL PSYCHIATRY 2013;25(2):141-148

CORRESPONDENCE: Brenda Vincenzi, MD Freedom Trail Clinic 25 Staniford Street Boston, MA 02114 USA E-MAIL: bvincenzi@partners.org
Annals of Clinical Psychiatry ©2013 Frontline Medical Communications Inc.

 
Read full article